Drug intelligence / Profile preview

Liqi Nuanwei Granules

Development stage: Unknown
Lead developer: Jiangxi Huiren Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Liqi Nuanwei Granules is a Traditional Chinese Medicine (TCM) formulation developed and manufactured by Jiangxi Huiren Pharmaceutical Co., Ltd. It is primarily indicated for the treatment of chronic superficial gastritis, specifically targeting the TCM syndrome of Qi stagnation and stomach cold. The preparation is designed to warm the middle burner (stomach), regulate Qi flow, and alleviate pain. Clinical symptoms addressed by this medication include epigastric distension, dull pain that improves with warmth or pressure, and acid regurgitation. As a multi-herb granule, it contains several botanical extracts that collectively exert gastroprotective, analgesic, and prokinetic effects.

Brand names: Huiren
Other names: Liqi Nuanwei Keli

Beyond the preview

Go deeper on Liqi Nuanwei Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liqi Nuanwei Granules.

Explore the full profile